TrianglePUBLICATIONS · 17065590
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2007 Feb
- First author
- Rocha-Lima CM
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Rocha-Lima CM
- type
- Author
- name
- Herndon JE 2nd
- type
- Author
- name
- Lee ME
- type
- Author
- name
- Atkins JN
- type
- Author
- name
- Mauer A
- type
- Author
- name
- Vokes E
- type
- Author
- name
- Green MR
- type
- Author
- name
- Cancer and Leukemia Group B
- type
- CollectiveName
Complete bibliographic record and source provenance
- authors
- name
- Rocha-Lima CM
- type
- Author
- name
- Herndon JE 2nd
- type
- Author
- name
- Lee ME
- type
- Author
- name
- Atkins JN
- type
- Author
- name
- Mauer A
- type
- Author
- name
- Vokes E
- type
- Author
- name
- Green MR
- type
- Author
- name
- Cancer and Leukemia Group B
- type
- CollectiveName
- bibliography ids
- nci-bib-bbbd3732f27f55a10deb06d7
- book metadata
- content sha256
- 3c650696c3d6ffdc9addc2d3e7bf54452317fc6410df2eac54276153c6e8dfcf
- document type
- citation
- dois
- 10.1093/annonc/mdl375
- electronic publication date
- display
- 2006 Oct 25
- precision
- day
- year
- 2006
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:17065590
- immutable id
- pubmed:17065590@3c650696c3d6ffdc9addc2d3e7bf54452317fc6410df2eac54276153c6e8dfcf
- journal
- abbreviation
- Ann Oncol
- issn electronic
- Source null
- issn print
- 0923-7534
- issue
- 2
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 331-7
- volume
- 18
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 17065590
- provenance
- batch id
- 2c499a3b9f4867a74c49
- provider
- NCBI PubMed ESummary
- record sha256
- 6b0887b6668dcff29a023a0b12a26c8a142dea211cda4fa14276f92157ec0170
- response sha256
- 3b299651c5c5270455877b65b6e5acff71ad5f85103b7f9582efe63c52588326
- retrieved at
- 2026-09-09T23:46:08.887541+00:00
- publication date
- display
- 2007 Feb
- precision
- month
- year
- 2007
- publication types
- Clinical Trial, Phase II
- Journal Article
- Research Support, N.I.H., Extramural
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Preserved source evidence · Not medical advice